Literature DB >> 32931147

The treatment journey for patients with axial spondyloarthritis in North Africa and the Middle East: From diagnosis to management.

Bassel El Zorkany1, Yaser Mustafa Ali2, Rajaie Namas3, Mohamed Bedaiwi4, Waleed Husain5, Haytham Mohamed Ahmed6, Nelly Ziade Zoghbi7.   

Abstract

The management of axial spondyloarthritis (axSpA) is challenging worldwide, and the particular challenges shared by North Africa and the Middle East are mainly related to early diagnosis and standardized management. We believe there are several reasons for these challenges, including: (a) limited awareness of the disease manifestations and prevalence in the region among physicians; (b) the concept of nonradiographic axSpA, while accepted with some difficulty by the rheumatology community, may not be well understood by the referring primary care physicians; (c) access to, and training in magnetic resonance imaging varies greatly between countries in the North Africa and Middle East region, and this may have a large impact on early diagnosis; (d) country-specific treatment guidelines are unavailable; and (e) economic and cultural factors influence patients' attempts to seek and continue treatment. In this review, we will discuss the prevalence of axSpA in North Africa and the Middle East, as well as the challenges to diagnose and treat patients in this region. As rheumatologists practicing in North Africa and the Middle East, we also provide suggestions to assist physicians, other healthcare professionals, and researchers in facilitating early, accurate diagnosis and treatment of axSpA.
© 2020 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Middle East; North Africa; axial spondyloarthritis; diagnosis; management; treatment

Year:  2020        PMID: 32931147     DOI: 10.1111/1756-185X.13961

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN: 1756-1841            Impact factor:   2.454


  2 in total

Review 1.  Expert recommendations on early diagnosis and referral of axial spondyloarthritis in the Kingdom of Saudi Arabia.

Authors:  Hanan Al Rayes; Mansour Alazmi; Khaled Alderaan; Mushabab Alghamdi; Nayef Alghanim; Ahmed Alhazmi; Nadeer Alkhadhrawi; Mohammad Almohideb; Zeyad Alzahrani; Mohamed Bedaiwi; Hussein Halabi; Suzan Attar
Journal:  Clin Rheumatol       Date:  2022-01-08       Impact factor: 2.980

2.  Long-Term Adherence to Etanercept in Treatment Effectiveness of Patients with Spondyloarthritis: 7-Year Data from the Iraq National Registry.

Authors:  Ali Abdulrahman Younis; Ali Hussein Al-Hafidh; Asal Adnan; Dina Yasiry; Nizar Abdulateef; Faiq I Gorial; Lyndon Llamado; Ali AlJabban
Journal:  Rheumatol Ther       Date:  2022-09-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.